Oslo (Norway), 25th April 2018 - Reference is made to the stock exchange announcement made on 25 April 2018 regarding PCI Biotech Holding ASA ("PCI Biotech" or the "Company") being approved for listing on Oslo Børs as a transfer from Oslo Axess.
In connection with the transfer of listing from Oslo Axess to Oslo Børs, the Company has now published a prospectus summary pursuant to section 7-2 of the Securities Trading Regulation. The summary prospectus is attached hereto and is also available at www.pcibiotech.com from today.
For further information, please contact:
Ronny Skuggedal, CFO
rs@pcibiotech.no
Mobile: +47 9400 5757
This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act.
